Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R ̣(sigma-2 receptor) complex. The company also intends to develop and advance candidates in the area of synucleinopathies. Cognition Therapeutics was incorporated in 2007 and is headquartered in Purchase, NY.
What is Cognition Therapeutics's quote symbol?
What is the 52 week high and low for Cognition Therapeutics (NASDAQ: CGTX)?
How much is Cognition Therapeutics stock worth today?
How much is Cognition Therapeutics's stock price per share?
What is Cognition Therapeutics's Market Cap?